Skip to main content

Past Event
13 July 2012


  • Joseph A. Mahoney
    T +1 312 701 8979

"Understanding New FDA’s Guidance on Biosimilar Product Development," Knowledge Congress, webcast panelist

July 13, 2012

The Food and Drug Administration released the first draft guidance on Biosimilar Products early February. The draft specifically contains 3 guidance documents on (1) Scientific Considerations; (2) Quality Considerations; and (3) Biosimilars: Questions and Answers Guidance. The issued guidance aims to help the pharmaceutical industry comply with the requirements under the BPCI Act and to successfully prove that their product is biosimilar to a biologic product approved by the FDA. The guidance raises many questions in the industry that have to be answered, including the cost of complying. 

Joseph A. Mahoney, Mayer Brown LLP

For more information or to register, please email Nura Williams at .

The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.